Tag: cancer immunotherapy
MAGE-A4/MAGE-A8-Targeted Bispecific T Cell Engager Shows Promise in Refractory Solid Tumors
Novel bispecific T cell engager IMA401 targeting MAGE-A4/MAGE-A8 shows encouraging safety and preliminary efficacy in phase 1a trial. Early results…
Single protein discovery could unlock CAR-T cell therapy’s full potential
Researchers identify NFIL3 protein as key barrier to CAR-T cell therapy success. Disabling this protein maintained stronger cancer-fighting activity in…
Submit Your Paper to GMJ
No APC until January 2027.